The effect of atropine on prevention of vasovagal syncope

The effect of atropine on prevention of vasovagal syncope before spinal anesthesia

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191231045957N1

Enrollment

100

Registered

2020-02-29

Start date

2020-01-21

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

effect of atropine on prevention of vasovagal syncope.

Interventions

Intervention group: Bupivacaine Half Percent Spinal For Spinal Anesthesia. Atropine sulfate 0.5 mg drug from Tehran-Iran Pharmaceutical Manufacturing Company (IRC): 0931701432667660 We will use for th

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patient's informed consent to participate in the study ASAII,III Female or male aged 15 to 60 years

Exclusion criteria

Exclusion criteria: People's unwillingness to participate in the study History of heart disease History of hypertension medications such as propranolol History of cigarette alcohol abuse and any drug abuse History of neurological disease

Design outcomes

Primary

Measure	Time frame
Atropine. Timepoint: Before the intervention, 15 minutes after the intervention and one hour after the intervention. Method of measurement: Milligram and questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Yahyaii.Behrouz

Islamic Azad University

nazanin.glz7474@gmail.com+98 23 3239 0360

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026